Why AP called Arizona for Trump
Trump wins Arizona, sweeping all seven battleground states, Edison Research says
China, Indonesia enhance ties with key deals on lithium, green energy, tourism
King Charles III and Kate will attend remembrance events as both royals slowly return to duty
Taliban administration officials to attend UN climate conference in Azerbaijan
Trump has vowed to kill US offshore wind projects. Will he succeed?
US to speed up interceptor missiles delivery to Ukraine, WSJ reports
Jalen Milroe runs for career-high 185 yards and 4 TDs as No. 11 Alabama thrashes No. 14 LSU 42-13
Justin Allgaier wins 1st NASCAR Xfinity title, capping comeback by passing Hill and Custer late
Evan Mobley scores 23 points and Cavaliers rally past Nets 105-100 to remain perfect at 11-0
(Reuters) - Intuitive Surgical beat Wall Street estimates for first-quarter profit and revenue on Thursday, riding on higher demand for its robots used in minimally invasive procedures.
Investor expectations around the performance of medical device makers have been heightened since last November, as people, especially older adults, opted for medical procedures deferred during the pandemic.
Intuitive, which makes surgical robots called da Vinci, earned $1.50 per share on an adjusted basis for the quarter ended March 31. Analysts on average estimated $1.41, according to LSEG data.
The company's sales rose 11% to $1.89 billion for the quarter, compared with the estimated $1.87 billion.
Worldwide, da Vinci procedures grew about 16% compared with the first quarter of 2023.
Shares of the California-based company were up more than 3% in trading after the bell.
Industry bellwether and rival Johnson & Johnson said on Tuesday it continues to expect medtech-related procedure volumes to remain elevated through 2024, despite missing estimates for its quarterly medical sales.
Brokerage Evercore ISI had then said a decline in sales for J&J's surgical devices likely reflects loss of market share to Intuitive.
Intuitive had forecast in January procedures using its da Vinci surgical robot to grow between 13% and 16% in 2024. That compares with an about 22% growth in 2023.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
